Pfizer Drug Fails to Beat Novartis’s Gleevec in Trial

Pfizer Inc.’s drug for leukemia wasn’t better than Novartis AG’s treatment Gleevec after a year, a study found.

The Pfizer drug, bosutinib, didn’t cut the amount of a tell-tale protein of the cancer in the blood better than Gleevec, New York-based Pfizer said in a statement today.

Bosutinib treats chronic myeloid leukemia, a slow- progressing cancer that causes bone marrow to produce too many white cells. The study was the third of three stages of testing usually required by the U.S. for regulatory approval.

The study followed 502 people, who previously hadn’t been treated, who received either Gleevec or bosutinib for a year. The trial is continuing.

Fewer patients who took bosutinib progressed to an advanced phase of the disease, and fewer died, according to the study. Almost 40 percent of people treated with bosutinib experienced a major molecular response, meaning that markers of bad blood cells were reduced at least 1,000-fold. That compares with 26 percent of people treated with Gleevec.

Pfizer said on Dec. 3 that it planned to submit bosutinib for regulatory approval in 2011.

Pfizer shares rose 9 cents to $16.81 in New York Stock Exchange composite trading at 4 p.m.

To contact the reporter on this story: Elizabeth Lopatto in New York at elopatto@bloomberg.net.

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.